| The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran M Ghaffari Darab, K Keshavarz, E Sadeghi, J Shahmohamadi, Z Kavosi BMC health services research 21, 1-7, 2021 | 145 | 2021 |
| Economic burden of hepatitis B virus-related diseases: evidence from iran K Keshavarz, A Kebriaeezadeh, SM Alavian, AA Sari, FA Dorkoosh, ... Hepatitis monthly 15 (4), e25854, 2015 | 59 | 2015 |
| Estimating the cost of illness of prostate cancer in Iran MM Mojahedian, M Toroski, K Keshavarz, M Aghili, S Zeyghami, S Nikfar Clinical therapeutics 41 (1), 50-58, 2019 | 31 | 2019 |
| Technical efficiency analyses in hospitals of Tabriz University of Medical Sciences A Feizollah, A Mohammad, K Khosro, D Alireza Hospital Journal 11 (2), 65-76, 2012 | 28 | 2012 |
| Effect of two major health reforms on health care cost and utilization in Fars Province of Iran: family physician program and health transformation plan M Bayati, K Keshavarz, F Lotfi, A KebriaeeZadeh, O Barati, S Zareian, ... BMC health services research 20, 1-9, 2020 | 27 | 2020 |
| Selective serotonin reuptake inhibitors in major depression disorder treatment: an umbrella review on systematic reviews M Ghaffari Darab, A Hedayati, E Khorasani, M Bayati, K Keshavarz International journal of psychiatry in clinical practice 24 (4), 357-370, 2020 | 26 | 2020 |
| Factors affecting the utilization of outpatient health services and importance of health insurance. F Lotfi, SN Motlagh, G Mahdavi, K Keshavarz, M Hadian, HA Gorji | 26 | 2017 |
| Cost‐Effectiveness analysis of biopharmaceuticals for treating rheumatoid arthritis: infliximab, adalimumab, and etanercept A Gholami, J Azizpoor, E Aflaki, M Rezaee, K Keshavarz BioMed Research International 2021 (1), 4450162, 2021 | 23 | 2021 |
| Computing cost price by using Activity Based Costing [ABC] method in radiology ward of Golestan hospital in Ahvaz University of medical sciences in 2009 A Torabi, K Keshavarz, Z Najafpour, M Mahmodi, E Mohamadil | 23 | 2011 |
| Economic burden of major depressive disorder: a case study in Southern Iran K Keshavarz, A Hedayati, M Rezaei, Z Goudarzi, E Moghimi, M Rezaee, ... BMC psychiatry 22 (1), 577, 2022 | 22 | 2022 |
| The effects of drug subsidies exclusion on price index of sectors and households expenditures; using structural path analysis KH KESHAVARZ, M ZAHIRI, I MIRIAN, A BEHESHTI, A IMANI, B NAJAFI, ... Journal of Health Administration 13 (42), 45-56, 2011 | 22 | 2011 |
| Pharmacists remuneration models in Iran and selected countries: a comparative study A Hashemi-Meshkini, K Keshavarz, S Nikfar, I Vazirian, A Kebriaeezadeh Iranian Journal of Pharmaceutical Research: IJPR 12 (4), 995, 2013 | 20 | 2013 |
| Financial perspective of private pharmacies in Tehran (Iran); is it a lucrative business? K Keshavarz, A Kebriaeezadeh, AH Meshkini, S Nikfar, I Mirian, ... DARU Journal of Pharmaceutical Sciences 20, 1-8, 2012 | 20 | 2012 |
| Survey of appropriate use of magnetic resonance imaging services provided in Shahid Chamran Hospital of Shiraz A Sadeghi, K Keshavarz, MS Ahmadzadeh, A Yousefi Journal of health research in community 1 (3), 33-40, 2015 | 18 | 2015 |
| Cost-effectiveness of rabies post exposure prophylaxis in Iran. N Hatam, F Esmaelzade, A Reza Mirahmadizadeh, K Keshavarz, ... Journal of Research in Health Sciences 14 (2), 2014 | 18 | 2014 |
| Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials K Keshavarz, F Lotfi, E Sanati, M Salesi, A Hashemi-Meshkini, M Jafari, ... DARU Journal of Pharmaceutical Sciences 25, 1-11, 2017 | 17 | 2017 |
| Is Taurolidine-citrate an effective and cost-effective hemodialysis catheter lock solution? A systematic review and cost-effectiveness analysis Z Kavosi, MS Khorrami, K Keshavarz, A Jafari, AH Meshkini, HR Safaei, ... Medical journal of the Islamic Republic of Iran 30, 347, 2016 | 17 | 2016 |
| COVID-19 reinfection rate and related risk factors in Fars Province, Iran: a retrospective cohort study A Tavakoli, F Lotfi, M Lotfi, M Bayati, M Seif, M Salesi, M Emadi, ... Iranian Journal of Medical Sciences 48 (3), 302, 2023 | 14 | 2023 |
| Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran M Rezaee, S Izadi, K Keshavarz, A Borhanihaghighi, R Ravangard Journal of medical economics 22 (4), 297-305, 2019 | 14 | 2019 |
| A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection SM Alavian, S Nikfar, A Kebriaeezadeh, F Lotfi, E Sanati, MR Hemami, ... Iranian Red Crescent Medical Journal 18 (11), e37094, 2016 | 13 | 2016 |
Shekoufeh NikfarProfessor of Pharmacoeconomics, Tehran University of Medical Sciences (TUMS), Iranכתובת אימייל מאומתת בדומיין tums.ac.ir
